In This Article:
Key Points
-
Eli Lilly's Q1 numbers showed strong revenue and earnings growth, driven by its GLP-1 offerings.
-
The company's 2025 outlook disappointed investors, however, leading to the decline.
-
The stock carries a hefty premium, but it is justified by the company's…